Combination Biologic Therapy for Severe Persistent Asthma

Biological pathways underlying severe asthma can be divided broadly into T2hi and T2low, with T2hi having a greater presence of type 2 innate lymphoid and helper T cells, the cytokines interleukin (IL)-4, IL-5, IL-13 and eosinophils, while T2low may show lack of inflammation or neutrophil predominance driven by Th1 and Th17 cells and the related cytokines IL-17 and interferon- γ.1-3 In the past few years, more targeted biologic therapies have become available which specifically block T2 pathways and for which biomarkers such as immunoglobulin E (IgE) or blood eosinophil levels are utilized.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research